Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck - Results of a phase II study of the EORTC Early Clinical Studies Group
Schöffski, Patrick × Catimel, G Planting, AST Droz, JP Verweij, J Schrijvers, D Gras, L Schrijvers, A Wanders, J Hanauske, AR #
Kluwer Academic Publishers
Annals of Oncology vol:10 issue:1 pages:119-122
Background. Docetaxel and cisplatin are among the most active antitumor agents in head and neck cancer, and phase I studies found the combination of the two drugs to be feasible. The EORTC ECSG performed a multicenter phase II study in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck to evaluate the antitumor efficacy and toxicity of this combination.